Bicocca Open Archive

Logo unimib boa
CAIROLI, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 12.755
EU - Europa 5.283
NA - Nord America 5.030
SA - Sud America 1.815
AF - Africa 181
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 2
Totale 25.092
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.837
SG - Singapore 4.677
CN - Cina 2.912
HK - Hong Kong 2.819
RU - Federazione Russa 1.874
BR - Brasile 1.508
IT - Italia 1.225
VN - Vietnam 960
IE - Irlanda 897
KR - Corea 590
DE - Germania 304
ID - Indonesia 222
SE - Svezia 198
GB - Regno Unito 195
IN - India 145
AR - Argentina 123
FI - Finlandia 94
NL - Olanda 86
AT - Austria 82
MX - Messico 81
CA - Canada 76
ZA - Sudafrica 76
BD - Bangladesh 72
UA - Ucraina 68
EC - Ecuador 62
ES - Italia 54
FR - Francia 51
TR - Turchia 49
JP - Giappone 45
IQ - Iraq 44
CO - Colombia 33
PK - Pakistan 30
MA - Marocco 26
VE - Venezuela 25
PL - Polonia 24
AU - Australia 23
CH - Svizzera 20
SA - Arabia Saudita 20
CL - Cile 19
KE - Kenya 19
UZ - Uzbekistan 19
PY - Paraguay 18
TN - Tunisia 18
JO - Giordania 16
PH - Filippine 16
PE - Perù 15
EG - Egitto 14
IR - Iran 14
BE - Belgio 13
NP - Nepal 13
LT - Lituania 12
LB - Libano 11
CZ - Repubblica Ceca 10
DK - Danimarca 10
IL - Israele 10
MY - Malesia 10
AZ - Azerbaigian 9
KZ - Kazakistan 9
PT - Portogallo 9
HR - Croazia 8
JM - Giamaica 8
TW - Taiwan 8
DO - Repubblica Dominicana 7
GR - Grecia 7
HU - Ungheria 7
UY - Uruguay 7
AE - Emirati Arabi Uniti 6
DZ - Algeria 6
OM - Oman 6
AL - Albania 5
BG - Bulgaria 5
ET - Etiopia 5
RO - Romania 5
BH - Bahrain 4
PA - Panama 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
AO - Angola 3
BA - Bosnia-Erzegovina 3
BO - Bolivia 3
CR - Costa Rica 3
GE - Georgia 3
GT - Guatemala 3
HN - Honduras 3
NO - Norvegia 3
PS - Palestinian Territory 3
SN - Senegal 3
UG - Uganda 3
AM - Armenia 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
EE - Estonia 2
GY - Guiana 2
KW - Kuwait 2
MK - Macedonia 2
NG - Nigeria 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
RS - Serbia 2
SI - Slovenia 2
Totale 25.074
Salva come PNG Salva come JPEG
Città #
Hong Kong 2.813
Singapore 2.771
Hefei 1.390
Dublin 846
Seoul 578
Ashburn 505
New York 435
Santa Clara 422
Milan 329
Ho Chi Minh City 313
Los Angeles 238
Hanoi 237
The Dalles 218
Dallas 203
Moscow 195
Beijing 185
Buffalo 181
Jakarta 179
São Paulo 158
Ann Arbor 125
Chicago 109
Nuremberg 107
Turin 92
Frankfurt am Main 86
Rome 74
Seattle 69
Shanghai 65
Fairfield 46
Helsinki 45
Rio de Janeiro 45
Desio 43
Chandler 42
Salt Lake City 42
Haiphong 41
London 40
Boardman 36
Munich 34
Vienna 34
Houston 33
Belo Horizonte 32
Tampa 32
Amsterdam 31
Johannesburg 30
Biên Hòa 27
Da Nang 27
Phoenix 27
Porto Alegre 27
Brasília 26
Curitiba 26
Tokyo 26
Washington 26
Wilmington 26
Lappeenranta 25
Montreal 25
Ha Long 23
Atlanta 22
Guangzhou 22
Quito 21
Jacksonville 20
Naples 20
Boston 19
Kent 19
Princeton 19
Redondo Beach 19
Brooklyn 18
Tashkent 18
Toronto 18
Warsaw 18
Bologna 17
Chennai 17
Elk Grove Village 17
Kilburn 17
Madrid 17
Mexico City 17
Salvador 17
Turku 17
Amman 16
Assago 16
Dearborn 16
Hyderabad 16
Miami 16
Mumbai 16
Ninh Bình 16
Stockholm 16
Cambridge 15
Campinas 15
Dhaka 15
Genoa 15
Lahore 15
Manchester 15
Nairobi 15
Ribeirão Preto 15
San Francisco 15
Ankara 14
Changsha 14
Cinisello Balsamo 14
Hải Dương 14
Joinville 14
Nanjing 14
New Delhi 14
Totale 14.590
Salva come PNG Salva come JPEG
Nome #
Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) 437
Assessing eligibility for treatment in acute myeloid leukemia in 2023 349
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 297
The role of quantitative polymerase chain reaction in the management of follicular lymphoma patients 226
Lymphoma’s last therapeutic option: Freeze it! 216
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients 207
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 205
Communicating the diagnosis of a hematological neoplastic disease to patients’ minor children: a multicenter prospective study 200
RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia 200
Impact of serial echocardiography in the management of primary cardiac lymphoma 194
Advances in the understanding of molecular genetics and therapy ofRichter transformation in chronic lymphocytic leukemia 186
Cerebral Infectious Opportunistic Lesions in a Patient with Acute Myeloid Leukaemia: The Challenge of Diagnosis and Clinical Management 183
Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study 173
KIT activating mutations: Incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication 158
Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical Trial 156
A phase I/IIa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis 152
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi 147
Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3 144
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial 142
Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review 141
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 136
Fasting and Diet: Overview in Chronic Lymphocytic Leukemia 131
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial 127
Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing–Neel Syndrome 125
Effectiveness and Tolerability of Dual Antiviral Therapy in Immunosuppressed Patients with Protracted SARS-CoV-2 Infection 124
Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial 124
Exploring the administrative burden faced by hematologists: a comprehensive study in Italy 123
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapy 122
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 119
Impaired survival of patients with non donor-specific anti-HLA antibodies before HLA-mismatched allogeneic stem cell transplantation 119
Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination.—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda 118
"Efficient Strategies for the Reuse of Surgical and FFP2/ KN95 Face Masks during the COVID-19 Pandemic: Home-Made and Ecological Choices for the Community" 115
Use of Sorafenib in FLT3-Mutant Myeloid Sarcoma: A Case Report 115
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities 114
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 111
In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation 110
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice 110
Myeloma’s multiple morphologies 108
Intrahospital COVID-19 infection outbreak management: Keep calm and carry on 106
Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) 105
Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy? 105
Hypoplasia of the Spleen: Rare and Puzzling 104
Transcriptomic Signature of a Patient with Chronic Lymphocytic Leukemia Exhibiting Profound Fluctuations in the Lymphocytosis during Nutrition and Prolonged Fasting Periods 103
Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial 101
Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy 101
Plasma cell-directed therapy and anti-HLA antibody production: A successful combination? 99
MIS-A: Beware of non-lymphoma 98
Cordycepin (3′dA) Induces Cell Death of AC133+ Leukemia Cells via Re-Expression of WIF1 and Down-Modulation of MYC 98
Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients 97
IN ADULT ACUTE MYELOID LEUKEMIA (AML) PERIPHERAL BLOOD MEASURABLE RESIDUAL DISEASE (MRD) BY FLOW CYTOMETRY (FC) IS FEASIBLE AND IS PROGNOSTICALLY RELEVANT 96
A novel start-loss mutation of the SH2B3 gene in a family with myeloproliferative neoplasms 96
Occurrence of L1M Elements in Chromosomal Rearrangements Associated to Chronic Myeloid Leukemia (CML): Insights from Patient-Specific Breakpoints Characterization 96
Saccharomyces cerevisiae fungemia with granulomas in the bone marrow in a patient undergoing BMT 95
Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an "Old-fashioned" Drug be Effective? 95
How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia 94
A Nine-Gene Expression Signature Distinguished a Patient with Chronic Lymphocytic Leukemia Who Underwent Prolonged Periodic Fasting 93
Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience 92
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma 91
Clinical management of peripherally inserted central catheters compared to conventional central venous catheters in patients with hematological malignancies: A large multicenter study of the REL GROUP (Rete Ematologica Lombarda - Lombardy Hematologic Network, Italy) 90
Dual antiviral therapy in haematological patients with protracted SARS-CoV-2 infection 90
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 88
c-kit activating mutations and mast cell proliferation in human leukemia [4] 88
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study 88
VENETOCLAX IN MULTI-RELAPSED MANTLE CELL LYMPHOMA PATIENTS: A REAL-LIFE MULTICENTRIC EXPERIENCE 87
Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: Results of an Italian multicenter study 87
Bone Marrow CD34+/lin− Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects 87
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma 86
Multidimensional Results and Reflections on CAR-T: The Italian Evidence 86
Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 86
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 85
Response of steroid-refractory chronic graft-versus-host disease to extracorporeal photopheresis correlates with the dose of CD3+ lymphocytes harvested during early treatment cycles 84
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913 83
Use of Plerixafor in Poor Mobilizer Patients with Myeloma and Lymphoma: Clonogenic Capacity and Engraftment Data 83
DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma 83
Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL) 83
PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation 82
PROGNOSTIC CORRELATION OF CELL-OF-ORIGIN AND MYC, BCL-2 AND BCL-6 STATUS IN HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS 82
Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19 82
Clinical Impact of Graft Cryopreservation on Allogeneic Stem Cell Transplantation: An Italian, Registry-Based Study on Behalf of the “Gruppo Italiano Per Il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare” (GITMO) 82
Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol 82
Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome 81
C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index 81
A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis 81
Tregs and GvHD prevention by extracorporeal photopheresis: observations from a clinical trial 80
Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment 80
Gastrointestinal Kaposi's Sarcoma in a Woman with Selective IgA Deficiency and prior Immunosuppressive therapy for Idiopathic Thrombocitopenioc Purpura 80
Prognostic impact of immunohistochemical p53 expression in bone marrow biopsy in higher risk MDS: A pilot study 79
Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects 79
Fungal infections in hematologic neoplasms: Autopsy findings 79
Detection of c-KIT antigen (CD117) and c-kit mRNA in acute leukemia 79
VERY LONG-TERM RESULTS OF ALL-TRANS RETINOIC ACID AND ARSENIC TRIOXIDE IN NON-HIGH RISK ACUTE PROMYELOCYTIC LEUKEMIA: LATEST UPDATE OF THE ITALIAN-GERMAN APL0406 RANDOMIZED TRIAL 79
Prognostic significance of CD33, CD34 and CD117 expression on bone marrow blasts of patients with Myelodysplastic syndromes 79
A phase I/II study of NMS-03592088, a FLT3, KIT and CSF1R inhibitor, in patients with relapsed or refractory AML or CMML 79
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial 78
Detection by polymerase chain reaction of BCR/ ABL transcripts in myeloproliferative diseases at time of diagnosis and for monitoring chronic myelogenous leukaemia patients after bone marrow transplantation 78
RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS OF THE AML1310 TRIAL OF THE GIMEMA GROUP 78
Management of patients with acute myeloid leukemia undergoing therapy with midostaurin: a focus on antifungal prophylaxis 78
Targeted Therapy in FLT3-ITD Positive Myeloid Sarcoma: Proof of Principle 78
IDENTIFICAZIONE DI MIRNA E GENI TARGET NELL’ANALISI TRASCRITTOMICA DELLE CELLULE CD34+/LIN- DI PAZIENTI CON LEUCEMIA MIELOIDE CRONICA IN FASE CRONICA DOPO 12 MESI DI TERAPIA CON NILOTINIB 78
Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience 77
Totale 11.684
Salva come PNG Salva come JPEG
Categoria #
all - tutte 117.594
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 117.594
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202166 0 0 0 0 0 11 12 12 14 6 3 8
2021/2022121 6 3 15 7 11 10 2 14 7 8 12 26
2022/20231.417 27 57 11 13 9 26 0 151 58 921 64 80
2023/20243.794 57 115 139 106 515 840 653 200 657 104 76 332
2024/20259.731 545 1.184 457 439 783 295 687 221 844 1.048 1.035 2.193
2025/202610.689 2.037 2.311 1.568 2.487 1.507 779 0 0 0 0 0 0
Totale 26.103